Genetic Susceptibility to Vaccine Adverse Reactions

Table of Contents

  1. Overview: Rare Is Not Nobody
  2. What the Package Insert Actually Says
  3. Immune Defects That Are Already Contraindications
  4. SCN1A and Dravet Syndrome: The Case That Changed the Question
  5. Excipient Allergy: Gelatin, Egg, PEG and Polysorbate
  6. Interferon-Pathway Defects in Otherwise Healthy Children
  7. What Screening Actually Exists Today
  8. What Does Not Exist — and Why It Is Hard
  9. Reading the Risk Numbers Honestly
  10. VAERS, the Vaccine Safety Datalink, and Compensation
  11. Practical Guidance for Families
  12. Key Research Papers
  13. Live PubMed Searches
  14. Connections
  15. Featured Videos

1. Overview: Rare Is Not Nobody

Two statements are both true, and most public argument about vaccines collapses because people insist on only one of them. The first: serious adverse reactions to routine vaccines are rare, and for the overwhelming majority of children the risk from the vaccine is far smaller than the risk from the disease it prevents. The second: rare is not zero. Some people do have severe reactions, a handful of them have identifiable biological reasons, and those reasons are increasingly findable.

This page is about the second statement, and specifically about a scientific question that follows from it: can we identify in advance who is at elevated risk? That question is legitimate, it is actively researched, and it is partly — but only partly — answered. For a small number of well-defined conditions the answer is a firm yes, and screening for them is already routine standard of care in the United States. For the general population of healthy children, the answer today is no, and this page explains both what exists and why the gap is harder to close than it first appears.

The field has a name: adversomics, the study of how individual genetic and immune variation drives vaccine adverse events, coined by analogy with vaccinomics (the study of variation in vaccine response). It is a real and funded research area, not a fringe one.

Nothing here is medical advice. Decisions about a specific child belong to that child's family and clinician, informed by the child's own history.

2. What the Package Insert Actually Says

Every FDA-licensed vaccine ships with a package insert — formally the prescribing information, written in a standardized format called Structured Product Labeling. It is a public document. You can read any of them at the FDA's licensed-vaccines page or at the National Library of Medicine's DailyMed database, without a prescription, an account, or a login.

Four sections matter most:

Section 6.2 is where the serious-sounding entries usually live — encephalitis, transverse myelitis, anaphylaxis, thrombocytopenia — and it is where careful reading matters most. These are reported events, not established causal effects, and the label itself says so. The standard wording notes that because the reports come voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.

That caveat cuts in both directions, and honesty requires holding both edges:

The practical point stands regardless of which edge you emphasize: a parent who wants to know what a vaccine's own label says can read it in about ten minutes, and the label is the correct starting document for that conversation.

3. Immune Defects That Are Already Contraindications

The clearest case of “we know who is at risk” is primary immunodeficiency. A live attenuated vaccine contains a weakened but replicating organism. In a person with a competent immune system it replicates briefly, provokes immunity, and is cleared. In a person who cannot mount that response, it can replicate without limit and cause the disease it was meant to prevent.

This is not theoretical. Infants with severe combined immunodeficiency who received live rotavirus vaccine before their SCID was recognized developed prolonged vaccine-strain rotavirus infection, documented in the New England Journal of Medicine in 2010. The same logic drives the standing rules across the immunodeficiencies the site covers:

Note what this list demonstrates. For these conditions, the “identify the susceptible child before vaccinating” program is not a proposal. It is settled practice, written into the labels, and in the case of SCID it is backed by universal newborn screening (Section 7).

4. SCN1A and Dravet Syndrome: The Case That Changed the Question

The single most instructive episode in this field concerns a group of children historically described as having vaccine encephalopathy: normal development, then a prolonged seizure within a day or two of a whole-cell pertussis vaccination, then intractable epilepsy and developmental regression. For decades this was the archetypal vaccine injury, and it drove litigation, compensation, and the reformulation of the pertussis vaccine.

In 2006, Berkovic and colleagues went back and sequenced these patients. Of 14 children carrying that diagnosis, 11 had de novo mutations in SCN1A, the gene encoding a neuronal sodium channel subunit — the established cause of Dravet syndrome, a severe genetic epilepsy whose natural history is precisely normal early development followed by fever-triggered prolonged seizures and regression. The mutations were new in the child, present in neither parent, and therefore present from conception, years before any vaccine was given.

A follow-up study by McIntosh and colleagues in 2010 asked the obvious next question: among children with genetically confirmed Dravet syndrome, does it matter whether the first seizure happened to follow a vaccination? Seizure onset in the vaccination-proximate group was earlier. But at later assessment, intellectual outcome and seizure outcome were no different between the vaccination-proximate and the non-proximate groups.

Read this honestly, because it does not fit either side's slogan:

The episode is also a caution about mechanism. “Susceptible” can mean several different things — the vaccine causes harm only in this genotype; or the vaccine triggers the timing of a harm that was coming anyway; or the vaccine is coincidental to an event at an age when that event is common. Only the first is vaccine injury in the ordinary sense. Distinguishing them requires exactly the kind of genetic work Berkovic did, which is an argument for funding that research, not against it.

5. Excipient Allergy: Gelatin, Egg, PEG and Polysorbate

The best-characterized true vaccine-caused severe reaction is anaphylaxis, and it is usually a reaction to an excipient — a manufacturing or stabilizing ingredient — rather than to the antigen.

McNeil and colleagues, using Vaccine Safety Datalink records across more than 25 million vaccine doses, estimated anaphylaxis at roughly 1.31 cases per million doses across all vaccines. That is the honest headline number: real, confirmed, causal, and very rare.

The known culprits:

The 2012 AAAAI/ACAAI practice parameter on adverse reactions to vaccines, still the operative clinical document, sets out the evaluation pathway: identify the suspected component, skin-test or measure specific IgE, and where a vaccine is still needed, give it in graded doses under observation. This is a working, deployed example of individualized pre-vaccination risk assessment — it is simply limited to people who already have a reason to be tested.

6. Interferon-Pathway Defects in Otherwise Healthy Children

Sections 3 and 5 cover children with an already-visible reason for concern — a diagnosed immunodeficiency, a known allergy. The harder and more interesting category is the child with no warning signs at all.

Two studies define it. Duncan and colleagues, in 2015, described a child with IFNAR2 deficiency who had a severe adverse reaction to MMR; the defect impaired type-I interferon signaling, which is the arm of immunity that controls a replicating live viral vaccine. Hernandez and colleagues, in 2019, described inherited IFNAR1 deficiency in patients the paper explicitly characterizes as otherwise healthy, who had adverse reactions to measles and yellow fever live vaccines.

The phrase “otherwise healthy” is the entire point. These children had no recurrent infections, no failure to thrive, nothing that would have triggered an immunologic workup. Their single-gene defect was narrow enough that a live attenuated vaccine was the first pathogen challenge that exposed it. No existing contraindication screen would have found them.

This is the honest scientific core of the argument that we do not yet know who is susceptible. It is not speculation — it is published, mechanistically explained, and gene-specific. It also shows the shape of the problem: these are ultra-rare inborn errors of immunity, found by sequencing after a severe event, in a small number of families.

7. What Screening Actually Exists Today

Four things genuinely exist and are in routine use:

  1. Newborn screening for SCID. The TREC assay — a PCR measurement of T-cell receptor excision circles on the standard newborn dried blood spot — detects infants with severe T-cell deficiency in the first days of life. Kwan and colleagues reported the results from 11 US screening programs in JAMA in 2014, covering more than three million infants, and established an incidence of typical SCID of roughly 1 in 58,000 births — substantially higher than pre-screening estimates. SCID screening is now performed in all 50 states. This is a universal, population-scale, pre-vaccination test that identifies children who must not receive live vaccines, and it works. Anyone arguing that such a program is impossible in principle has to account for the fact that the United States already runs one.
  2. Allergy evaluation for suspected excipient allergy. Skin testing and specific-IgE for gelatin, egg, PEG, and polysorbate, per the 2012 practice parameter, with graded-dose administration under observation when a vaccine is still indicated.
  3. Clinical history. A prior severe reaction to a specific vaccine or a known severe allergy to a named component is itself a labeled contraindication. Family history of a diagnosed inborn error of immunity triggers evaluation before live vaccines.
  4. Post-event genetic testing. After an unexplained severe neurological event following vaccination, epilepsy gene panels including SCN1A are standard. This is diagnostic rather than predictive — it explains what happened, it does not screen the next child — but it is what converted “vaccine encephalopathy” into Dravet syndrome.

8. What Does Not Exist — and Why It Is Hard

There is no general-population blood, urine, or breath test that predicts vaccine adverse-reaction risk in a healthy child with no red flags. That is a plain statement of the current state of the art, and it is what makes the proposal a research program rather than a policy that could be adopted next year.

The obstacles are worth stating precisely, because they are technical rather than political:

The fair summary: the goal is scientifically respectable and partially achieved; the specific vision of a quick pre-vaccination screening test for every child is not close, and the reason is the base rate rather than a lack of will. The path that has actually worked — SCID newborn screening — succeeded because the condition is catastrophic, the assay is cheap, and the test rides on a blood spot that was already being collected. Extensions are most likely to come the same way.

9. Reading the Risk Numbers Honestly

Arguments about vaccine risk are frequently won or lost on the choice of denominator, and both sides do it. The measles case is the clearest illustration.

Before the vaccine was licensed in 1963, the CDC's figures for the United States are an estimated 3 to 4 million infections annually, with roughly 400 to 500 deaths, about 48,000 hospitalizations, and about 1,000 cases of encephalitis each year. From those same numbers you can construct two very different-sounding statistics:

The two figures differ by roughly fiftyfold and neither is fabricated. The per-population figure is the wrong denominator for a personal decision, because in the pre-vaccine era essentially every child was infected; the relevant question was never “what is my chance of dying of measles this year” but “what happens when I get it, which I will.”

Two further points belong in an honest accounting of measles severity:

The same discipline applies in the other direction. Anaphylaxis at 1.31 per million doses is the correct denominator for vaccine anaphylaxis risk, and quoting raw VAERS report counts without a dose denominator inflates it just as badly as the per-population trick deflates measles. Ask what the denominator is, every time, whoever is talking.

For the related question of whether the number of vaccines given together overwhelms an infant's immune capacity, Offit and colleagues addressed the immunologic arithmetic directly in 2002, and DeStefano and colleagues tested cumulative antigen exposure against autism risk in a case-control study in 2013 and found no association. Both are cited in full below.

10. VAERS, the Vaccine Safety Datalink, and Compensation

Three separate systems are routinely confused with one another.

VAERS (the Vaccine Adverse Event Reporting System) is a passive, open surveillance system co-run by CDC and FDA. Anyone — clinician, parent, patient — can file a report, and reports are not verified before entry. Shimabukuro and colleagues describe its design and its limits in a 2015 review: it is a hypothesis-generating system, deliberately built to be over-inclusive so that unexpected signals surface early. It cannot establish causation, its denominators are unknown, and it is subject to both under-reporting and stimulated reporting driven by publicity or litigation. Its successes are real — it caught the rotavirus-intussusception signal that pulled RotaShield from the market in 1999.

Both common misuses follow from ignoring what it is. Citing a raw VAERS count as a measure of vaccine harm treats unverified reports as confirmed injuries. Dismissing VAERS as useless discards the system that has actually detected several real safety signals.

The Vaccine Safety Datalink (VSD) is the controlled counterpart: linked electronic health records from a set of large health systems, with real denominators and comparison groups, used to test the hypotheses VAERS generates. The 1.31-per-million anaphylaxis figure comes from VSD, not VAERS, and that is precisely why it can be stated as a rate.

Compensation runs through two programs. The National Vaccine Injury Compensation Program (NVICP), created by the National Childhood Vaccine Injury Act of 1986, is a no-fault system funded by an excise tax of $0.75 per vaccine antigen dose. Claims for conditions on the Vaccine Injury Table occurring within specified time windows are presumed vaccine-related without proof of causation; other claims must prove causation. Separately, the Countermeasures Injury Compensation Program (CICP) handles products covered by a PREP Act declaration, including COVID-19 vaccines; it has a shorter filing window, a narrower benefits structure, and no independent appeal to a court, and it has been widely criticized on those grounds from across the political spectrum.

The existence of NVICP is itself a piece of evidence worth stating plainly: the United States government has operated a vaccine-injury compensation program for four decades. That is a formal, funded acknowledgment that a small number of people are injured by vaccines, and it is not in dispute.

11. Practical Guidance for Families

What is actually actionable, given the above:

  1. Read the insert for the specific product. Look it up on DailyMed by brand name. Read Section 4 first — contraindications are short, specific, and the part that might apply to you.
  2. Know your family history of immunodeficiency. Recurrent unusual infections, failure to thrive, an infant death from infection, or a diagnosed inborn error of immunity in a relative are all reasons to raise live vaccines with a clinician before the visit, not during it.
  3. Confirm the newborn SCID screen was done and was normal. It is part of the standard newborn blood spot in all 50 states, and it is the single most consequential pre-vaccination test that exists.
  4. Take a prior reaction seriously and get it characterized. A documented severe reaction to a previous dose is a labeled contraindication. Allergy referral can identify the responsible excipient, which frequently allows other vaccines to be given safely.
  5. Report events to VAERS. The system only works as a signal detector if events are reported. Reporting is not a claim of causation.
  6. Be skeptical of any denominator-free number, from any source, in either direction.

None of this substitutes for a clinician who knows the child's history.

12. Key Research Papers

Peer-reviewed sources for every substantive claim above. Each citation links to the full text via DOI.

  1. Berkovic SF, Harkin L, McMahon JM, et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. The Lancet Neurology. 2006;5(6):488–492.
  2. McIntosh AM, McMahon J, Dibbens LM, et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. The Lancet Neurology. 2010;9(6):592–598.
  3. Hernandez N, Bucciol G, Moens L, et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. Journal of Experimental Medicine. 2019;216(9):2057–2070.
  4. Duncan CJA, Mohamad SMB, Young DF, et al. Human IFNAR2 deficiency: lessons for antiviral immunity. Science Translational Medicine. 2015;7(307):307ra154.
  5. Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. New England Journal of Medicine. 2010;362(4):314–319.
  6. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–738.
  7. McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. Journal of Allergy and Clinical Immunology. 2016;137(3):868–878.
  8. Stone CA, Liu Y, Relling MV, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. The Journal of Allergy and Clinical Immunology: In Practice. 2019;7(5):1533–1540.e8.
  9. Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. Journal of Allergy and Clinical Immunology. 2012;130(1):25–43.
  10. Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398–4405.
  11. Wendorf KA, Winter K, Zipprich J, et al. Subacute sclerosing panencephalitis: the devastating measles complication that might be more common than previously estimated. Clinical Infectious Diseases. 2017;65(2):226–232.
  12. Offit PA, Quarles J, Gerber MA, et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics. 2002;109(1):124–129.
  13. DeStefano F, Price CS, Weintraub ES. Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines is not associated with risk of autism. The Journal of Pediatrics. 2013;163(2):561–567.

Live PubMed Searches

  1. adversomics
  2. vaccine adverse event genetic susceptibility
  3. SCN1A vaccine encephalopathy
  4. inborn errors of immunity live vaccine complications
  5. polyethylene glycol hypersensitivity vaccine
  6. TREC newborn screening SCID
  7. gelatin allergy vaccine anaphylaxis
  8. type I interferon deficiency yellow fever vaccine
  9. subacute sclerosing panencephalitis incidence
  10. Vaccine Safety Datalink methodology

External Resources

Connections

↑ Back to Table of Contents